How often should people with diabetes have eye exams?

Most guidelines recommend a dilated eye examination or validated retinal imaging at least annually, beginning at diagnosis for type 2 diabetes and within five years of diagnosis for type 1, with more frequent follow-up if retinopathy is present.

What is the leading cause of vision loss in diabetic retinopathy?

Diabetic macular edema is the most common cause of vision loss, and it can occur at any stage of retinopathy, which is why macular OCT is a key part of monitoring.

Can diabetic retinopathy be reversed?

Good systemic control and treatment can stabilize and partially improve disease, and anti-VEGF therapy can reduce edema and regress neovascularization, but established ischemic damage may be permanent.

RetinaOphthalmologyOptometry

Diabetic Retinopathy

Also known as: DR, Diabetic eye disease

Overview

Diabetic retinopathy is a microvascular complication of diabetes mellitus and a leading cause of vision loss among working-age adults. It progresses from non-proliferative changes—microaneurysms, hemorrhages, and exudates—to proliferative disease with neovascularization that risks vitreous hemorrhage and tractional detachment. Glycemic and blood pressure control plus timely screening are the foundation of prevention.

LinkedIn Facebook X

Cause: Chronic hyperglycemia
Stages: Non-proliferative, proliferative
Vision-threatening: DME and proliferative DR
Prevention: Glycemic/BP control + screening

Key clinical points

Diabetic macular edema is the most common cause of vision loss in diabetic retinopathy and can occur at any stage.
Proliferative disease is defined by retinal or optic disc neovascularization.
Annual dilated screening (or validated imaging) is recommended for patients with diabetes.
Anti-VEGF therapy is first-line for center-involving DME and can regress neovascularization.
Panretinal photocoagulation remains important for high-risk proliferative disease.

Pathophysiology and staging

Chronic hyperglycemia damages retinal capillaries, producing microaneurysms, increased vascular permeability, and capillary nonperfusion. Non-proliferative diabetic retinopathy is graded mild to severe based on hemorrhages, venous beading, and intraretinal microvascular abnormalities. Progressive ischemia drives VEGF release and proliferative disease.

Diabetic macular edema—fluid accumulation in the central retina—can develop at any stage and is a leading cause of central vision loss.

Screening and diagnosis

Because early disease is asymptomatic, guidelines recommend regular dilated examination or validated retinal imaging beginning at diagnosis for type 2 diabetes and within five years for type 1. OCT quantifies macular edema, and widefield imaging and angiography map ischemia and neovascularization.

Documentation of severity guides follow-up intervals and referral, and communication with the patient’s medical team supports systemic control.

Treatment

Optimizing glycemic control, blood pressure, and lipids reduces incidence and progression. For center-involving diabetic macular edema, intravitreal anti-VEGF therapy is first-line, with corticosteroid implants and focal laser as adjuncts.

Proliferative disease is treated with panretinal photocoagulation and/or anti-VEGF therapy; vitrectomy addresses non-clearing vitreous hemorrhage or tractional retinal detachment.

Diabetic Retinopathy videos

Retina

Ozempic and Diabetic Retinopathy? -Dr. Shani Esparaz

Frequently asked questions

How often should people with diabetes have eye exams?: Most guidelines recommend a dilated eye examination or validated retinal imaging at least annually, beginning at diagnosis for type 2 diabetes and within five years of diagnosis for type 1, with more frequent follow-up if retinopathy is present.
What is the leading cause of vision loss in diabetic retinopathy?: Diabetic macular edema is the most common cause of vision loss, and it can occur at any stage of retinopathy, which is why macular OCT is a key part of monitoring.
Can diabetic retinopathy be reversed?: Good systemic control and treatment can stabilize and partially improve disease, and anti-VEGF therapy can reduce edema and regress neovascularization, but established ischemic damage may be permanent.

References & further reading

Retina

Diabetic Macular Edema

Diabetic macular edema (DME) is the accumulation of fluid in the central retina due to breakdown of the blood–retinal barrier in diabetes, and it is the most common cause of vision loss in patients with diabetic retinopathy. It can occur at any stage of retinopathy. OCT has made diagnosis and monitoring precise, and anti-VEGF therapy is the first-line treatment for center-involving disease.

Clinical overview Retina

Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is a progressive disease of the central retina and a leading cause of irreversible central vision loss in people over 50. It is divided into non-neovascular (dry) disease, marked by drusen and, in advanced form, geographic atrophy, and neovascular (wet) disease, in which choroidal neovascularization threatens rapid vision loss. Anti-VEGF therapy transformed the prognosis of wet AMD.